Home›Stock Screener›Tatva Chintan Pharma

Tatva Chintan Pharma Share Price Today | Stock Price & Tatva Chintan Pharma Share Screener

TATVA Chemicals & Petrochemicals
Live Share Price NSE
₹1648.90
▼ -11.90 (-0.72%)
2026-11-18 00:00:00
Live Share Price BSE
₹1647.05
▼ -12.50 (-0.75%)
2026-11-18 00:00:00

As of November 18, 2026, the live Tatva Chintan Pharma share price (NSE: TATVA) is ₹1,648.90 on NSE and ₹1,647.05 on BSE, down 0.72% from the previous close, with shares trading between ₹1,620.10 and ₹1,667.20 in today's trading session, and a 52-week range of ₹1,052.40–₹1,991.20. Track Tatva Chintan Pharma market cap to gauge the company's total market size. Use the Tatva Chintan Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Tatva Chintan Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹134 and net income of ₹10, with EBITDA of ₹28, an operating margin of 21.0% and a profit margin of 7.5%.

Tatva Chintan Pharma Market Cap ₹3,884.95 Cr.
TATVA P/E Ratio (TTM) 61.60
Tatva Chintan Pharma P/B Ratio 4.76
EPS (TTM) ₹17.98
Dividend Yield 0.12%
Debt to Equity 0.10
TATVA 52 Week High ₹1991.20
Tatva Chintan Pharma 52 Week Low ₹1052.40
Operating Margin 21.00%
Profit Margin 7.46%
TATVA Revenue (TTM) ₹134.00
EBITDA ₹28.00
Net Income ₹10.00
Total Assets ₹1,004.00
Total Equity ₹782.00

Tatva Chintan Pharma Share Price Chart

Track the current stock price of Tatva Chintan Pharma with an interactive chart. Analyse TATVA share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Tatva Chintan Pharma stock quote in one place.

The quote of ₹1,648.90 sits between the 52-week low of ₹1,052.40 and the 52-week high of ₹1,991.20, and the latest session moved -0.72% from the previous close.

Tatva Chintan Pharma Company Profile - Fundamental Screener

Screen Tatva Chintan Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for TATVA shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Chemicals sector and the Chemicals & Petrochemicals industry, and it trades under ISIN INE0GK401011.

Company Details

Classification

Sector Chemicals
Industry Chemicals & Petrochemicals
Sub-Sector Chemicals & Petrochemicals
Segment E

Identifiers and Leadership

ISIN INE0GK401011

Tatva Chintan Pharma Balance Sheet Screener

Screen TATVA balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹1,004, up from ₹836 in 2025.

Latest statistics put total assets at ₹1,004 and shareholder funds at ₹782, with a leverage ratio of 0.10.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018

Assets

Total Assets 1,004 836 819 759 658 315 249 188 0
Current Assets 0 0 0 0 0 0 0 0 0
Fixed Assets 609 526 427 196 160 120 111 67 0

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0
Current Liabilities 9 1 2 5 14 31 44 35 0
Non-Current Liabilities 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 782 739 737 515 473 166 118 80 0
Share Capital 23 23 23 22 22 20 8 8 0
Reserves & Surplus 758 715 714 493 451 146 110 72 0

Tatva Chintan Pharma Income Statement Screener - Profit & Revenue Analysis

Screen Tatva Chintan Pharma income statement and profit fundamentals. Analyze TATVA quarterly results. Tatva Chintan Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹134 and net profit was ₹10, equal to earnings per unit of ₹4.41, at an operating margin of 21%.

In that period expenses were ₹106, interest cost ₹1 and tax ₹6. The next period listed, 2026-Jun, shows revenue of ₹170 and net profit of ₹16.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 134 170 219 109 118 125 133 103 107 84 86 125 115 97 85
Expenses 106 136 177 99 100 101 106 83 93 78 79 112 93 76 73

Operating Costs and Margins

EBITDA 28 34 42 10 19 23 27 20 14 6 7 14 22 21 12
Operating Profit % 21.00% 19.00% 19.00% 8.00% 15.00% 18.00% 19.00% 16.00% 12.00% 7.00% 8.00% 10.00% 19.00% 21.00% 13.00%
Depreciation 10 11 11 7 9 9 9 6 7 7 7 3 6 7 7
Interest 1 2 3 0 0 1 1 0 0 0 0 3 3 3 0

Profit and Earnings

Profit Before Tax 17 21 29 2 9 14 18 14 7 -1 0 8 13 11 5
Tax 6 5 8 1 3 4 3 4 2 0 0 -9 4 3 2
Net Profit 10 16 22 1 7 10 15 10 5 -1 0 17 10 8 4
EPS 4.41 6.83 9.17 0.44 2.84 4.24 6.49 4.11 2.23 -0.29 0.06 7.65 4.29 3.43 1.48

Tatva Chintan Pharma Cash Flow Screener - Liquidity Fundamentals

Screen TATVA cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹32, and net cash flow was an outflow of ₹6.

Over the same period, investing activities used ₹116 and financing activities provided ₹79.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March

Cash from Operations and Investing

Operating Activities 32 25 98 28 20 20 25 7 13
Investing Activities -116 -65 -121 -101 -197 -21 -40 -17 -30

Financing and Net Cash

Financing Activities 79 17 31 38 235 -5 10 17 7
Net Cash Flow -6 -24 8 -36 59 -6 -5 8 -10

Tatva Chintan Pharma Shareholding Pattern Screener

See Tatva Chintan Pharma shareholding pattern with promoter, FII, and DII holdings. Check Tatva Chintan Pharma promoter holding and ownership changes for TATVA on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 72.02%, foreign institutions 3.82%, domestic institutions 2.99% and the public 18.32%, spread across 66,842 shareholders.

The shareholder count was 66,842 in 2026-Mar, compared with 64,921 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar

Promoter Holding

Promoter Holding 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02% 72.02%

Institutional Investors

FII Holding 3.82% 3.93% 4.38% 3.30% 3.26% 3.39% 4.17% 3.65%
DII Holding 2.99% 3.11% 3.21% 5.46% 5.11% 3.86% 3.33% 12.84%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 18.32% 17.48% 17.08% 16.92% 17.47% 18.29% 17.91% 10.49%
Other Holding 2.85% 3.45% 3.30% 2.30% 2.14% 2.44% 2.57% 1.00%
Shareholder Count 66,842 64,921 62,888 78,393 76,792 73,331 68,657 73,730

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Tatva Chintan Pharma. Tatva Chintan Pharma dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹2.00 per unit for 2026-March, a yield of 0.12%, compared with ₹1.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹2.00, ₹1.00 and ₹2.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹2.00 0.12%
2025-March ₹1.00 0.10%
2024-March ₹2.00 0.30%
2023-March ₹2.00 0.19%
2022-March ₹2.00 0.12%
2021-March ₹5.00 0.22%
2020-March ₹0.00 0.00%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Tatva Chintan Pharma Stock Index Membership - Nifty & Sensex

See which indices include Tatva Chintan Pharma stock. Check TATVA index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 3 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX CARBON, BSE INDEX SMLCAP.

Complete Index List

BSE 1000
BSE INDEX CARBON
BSE INDEX SMLCAP

Tatva Chintan Pharma Market Events Screener - Corporate Actions

Get Tatva Chintan Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Tatva Chintan Pharma stock events that may affect TATVA share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated October 19, 2026, with a record date of October 19, 2026.

It is followed by Annual General Meeting dated September 25, 2026 and Dividend dated September 11, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-10-19 2026-10-19 Quarterly Result Announcement NA 7.51%
2026-09-25 2026-09-25 Annual General Meeting NA 7.61%
2026-09-11 2026-09-11 Dividend ₹ 2.00 /share 26.92%
2026-07-17 2026-07-17 Quarterly Result Announcement NA 14.30%
2026-05-16 2026-05-16 Quarterly Result Announcement NA -0.67%
2026-01-21 2026-01-21 Quarterly Result Announcement NA 8.22%
2025-10-31 2025-10-31 Quarterly Result Announcement NA 5.47%
2025-09-26 2025-09-26 Annual General Meeting NA -2.06%
2025-09-12 2025-09-12 Dividend ₹ 1.00 /share 42.95%
2025-07-24 2025-07-24 Quarterly Result Announcement NA 5.55%
2025-05-02 2025-05-02 Quarterly Result Announcement NA -7.28%
2025-01-28 2025-01-28 Quarterly Result Announcement NA -3.45%
2024-10-25 2024-10-25 Quarterly Result Announcement NA -5.26%
2024-09-20 2024-09-20 Annual General Meeting NA -2.87%
2024-09-06 2024-09-07 Dividend ₹ 2.00 /share -20.78%

Tatva Chintan Pharma Competitors Screener - Peer Stocks Comparison

Screen TATVA competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Chemicals sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Solar Industries 169,796 72.90 9,966 30.94% 1,737 44.30
Pidilite Industries 156,204 57.90 14,867 11.05% 2,471 51.75
SRF 73,496 32.00 15,894 7.20% 1,835 54.59
Linde 58,727 119.30 2,549 -0.17% 549 69.67
Gujarat Fluorochemicals 52,201 80.20 5,126 5.63% 574 58.95
Navin Fluorine International 50,343 55.60 3,379 41.21% 664 69.89
Himadri Speciality Chemical 28,319 32.20 4,832 3.60% 755 44.85
Aether Industries 22,069 87.10 1,181 34.17% 220 55.95
Deepak Nitrite 21,688 20.50 7,947 -5.01% 551 54.64
Deepak Fertilisers & Petrochemicals 18,225 14.70 11,609 12.11% 739 70.36

Tatva Chintan Pharma Company Announcements - News & Reports Screener

Screen TATVA latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated October 20, 2026.

The next most recent announcements are dated October 19, 2026 and October 19, 2026.

Date Update Actions
2026-10-20 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-10-19 Updated Investor Presentation -
2026-10-19 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-10-19 Intimation Regarding Cancellation Of Schedule Of Earnings Call -
2026-10-19 Board Meeting Outcome for Board Meeting Outcome For Outcome Of The Board Meeting Held On 19.10.2026 -
2026-10-19 Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September2026 -
2026-10-16 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-13 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-12 Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Monday 19.10.2026 -
2026-10-06 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-09-26 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-25 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-23 Closure of Trading Window -
2026-09-17 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-08 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-09-08 Announcement under Regulation 30 (LODR)-Credit Rating -
2026-08-28 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-27 Intimation Of Record Date Book Closure And Cut-Off Date Pursuant To Regulation 42 And 44 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI Listing Regulations) -
2026-08-27 Business Responsibility and Sustainability Reporting (BRSR) -
2026-08-27 Reg. 34 (1) Annual Report. -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹1,648.90, within a 52-week range of ₹1,052.40 to ₹1,991.20. The P/E ratio is 61.60 and the P/B ratio is 4.76, with earnings per unit of ₹17.98. Market capitalisation stands at ₹3,884.95 Cr and the dividend yield is 0.12%. The company operates in the Chemicals sector, in the Chemicals & Petrochemicals industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 18, 2026. This page covers 9 balance sheet periods, 15 income statement periods, 9 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.